Sage Journals: Discover world-class research

Abstract

Herein we described the synthesis of siRNA-NES (nuclear export signal) peptide conjugates by solid phase fragment coupling and the application of them to silencing of bcr/abl chimeric gene in human chronic myelogenous leukemia cell line K562. Two types of siRNA-NES conjugates were prepared, and both sense strands at 5′ ends were covalently linked to a NES peptide derived from TFIIIA and HIV-1 REV, respectively. Significant enhancement of silencing efficiency was observed for both of them. siRNA-TFIIIA NES conjugate suppressed the expression of BCR/ABL gene to 8.3% at 200 nM and 11.6% at 50 nM, and siRNA-HIV-1REV NES conjugate suppressed to 4.0% at 200 nM and 6.3% at 50 nM, whereas native siRNA suppressed to 36.3% at 200 nM and 30.2% at 50 nM. We could also show complex of siRNA-NES conjugate and designed amphiphilic peptide peptideβ7 could be taken up into cells with no cytotoxicity and showed excellent silencing efficiency. We believe that the complex siRNA-NES conjugate and peptideβ7 is a promising candidate for in vivo use and therapeutic applications.

Get full access to this article

View all access options for this article.

References

van Ommen

G-JB

and Aartsma-Rus

. (2013). Advances in therapeutic RNA-targeting. N Biotechnol, 30:299–301.

Gavrilov

and Saltzman

. (2012). Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med, 85:187–200.

Burnett

and Rossi

. (2012). RNA-based therapeutics: current progress and future prospects. Chem Biol, 19:60–71.

Koo

and Wood

. (2013). Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy. Hum Gene Ther, 24:479–88.

Echigoya

and Yokota

. (2014). Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Nucleic Acid Ther, 24:57–68.

Arechavala-Gomeza

, Khoo

and Aartsma-Rus

. (2014). Splicing modulation therapy in the treatment of genetic diseases. Appl Clin Genet, 7:245–52.

Spitali

and Aartsma-Rus

. (2012). Splice modulating therapies for human disease. Cell, 148:1085–1088.

Wang

, Liu

, Zheng

and Chen

. (2014). Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities. Biotechnol Adv, 32:831–43.

Lee

, Yoon

and Cho.

(2013). Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed Res Int, 2013:782041.

10.

Pan

, Thompson

, Meng

, Wu

, Xu

. (2011). Tumor-targeted RNA-interference: functional non-viral nanovectors. Am J Cancer Res, 1: 25–42.

11.

Wang

, Li

, Han

, Liang

and Ji

. (2010). Nanoparticle-based delivery system for application of siRNA in vivo. Curr Drug Metab, 11:182–96.

12.

Yin

, Kanasty

, Eltoukhy

, Vegas

, Dorkin

, and DG

Anderson

. (2014). Non-viral vectors for gene-based therapy. Nat Rev Genet, 15:541–55.

13.

Winkler

. (2013). Oligonucleotide conjugates for therapeutic applications. Ther Deliv, 4:791–809.

14.

Juliano

, Ming

and Nakagawa

. (2012). The chemistry and biology of oligonucleotide conjugates. Acc Chem Res, 45:1067–1076.

15.

Jeong

, Mock

, Oh

Y-K

and Park

. (2009). siRNA conjugate delivery systems. Bioconjugate Chem, 20:5–14.

16.

Dijk

, Venkatesan

and Kim

. (2006). Peptide conjugates of oligonucleotides: synthesis and applications. Chem Rev, 106:3712–3761.

17.

Kubo

, Morikawa

, Ohba

and Fujii

. (2003). Synthesis of DNA-peptide conjugates by solid-phase fragment condensation. Org Lett, 5:2623–2626.

18.

Kubo

, Zhelev

, Rumiana

, Ohba

, Doi

and Fujii

. (2005). Controlled intracellular localization and enhanced antisense effect of oligonucleotides by chemical conjugation. Org Biomol Chem, 3:3257–3259.

19.

Murao

and Fujii

. (2009). Organic synthesis and antisense effects of oligonucleotide-peptide conjugates. Curr Organ Chem, 13:1366–1377.

20.

Schirle

and MacRae

. (2012). The crystal structure of human argonaute2. Science, 336:1037–1040.

21.

Elkayam

, Kuhn

, Tocilj

, Haase

, Greene

, Hannon

and Joshua-Tor

. (2012). The structure of human argonaute-2 in complex with miR-20a. Cell, 150:100–110.

22.

Fridell

, Fischer

, Luhrmann

, Meyer

, Meinkoth

, Malim

and Cullen

. (1996). Amphibian transcription factor IIIA proteins contain a sequence element functionally equivalent to the nuclear export signal of human immunodeficiency virus type 1. Rev Proc Natl Acad Sci U S A, 93:2936–2940.

23.

Hanas

, Hocker

, Cheng

, Lerner

, Brackett

, Lightfoot

, Hanas

, Madhusudhan

and Moreland

. (2002). cDNA cloning, DNA binding, and evolution of mammalian transcription factor IIIA. Gene, 282:43–52.

24.

Ginsberg

, King

and Roeder

. (1984). Xenopus 5S gene transcription factor, TFIIIA: Characterization of a cDNA clone and measurement of RNA levels throughout development. Cell, 39:479–489.

25.

Malim

, McCarn

, Tiley

and Cullen

. (1991). Mutational definition of the human immunodeficiency virus Type 1 Rev activation domain. J Virol, 65:4248–4254.

26.

Fujii

, Hasegawa

, Niidome

and Aoyagi

. (1999). Enhancement of stability of double and triple stranded DNA by cationic amphiphilic α-Helix peptide. Nucleosides Nucleotides, 6:1623–1624.

27.

Fujii

, Hasegawa

, Niidome

and Aoyagi

. (1999). Thermal stability of double and triple stranded DNA in the presence of cationic amphiphilic α-helix peptide. Pept Sci, 1998:297–300.

28.

Yokoyama

, Kubo

and Fujii

. (2001). Amphiphilic β-sheet peptides can bind to double and triple stranded DNA. Nucleosides Nucleotides Nuc Acids, 20:1317–1320.

29.

Kubo

, Yokoyama

, Ueki

, Abe

, Goto

, Niidome

, Aoyagi

, Iwakuma

, Ando

, Ono

and Fujii

. (2001). Design, synthesis and characterization of DNA binding peptides. Pept Sci, 2000:109–112.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.10 MB

0.06 MB

0.20 MB

Silencing of BCR/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates

Abstract

Get full access to this article

References

Supplementary Material